Design and synthesis of disubstituted thiophene and thiazole based inhibitors of JNK

From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorg. Med. Chem. Lett 2010-12, Vol.20 (24), p.7303-7307
Hauptverfasser: Hom, Roy K., Bowers, Simeon, Sealy, Jennifer M., Truong, Anh P., Probst, Gary D., Neitzel, Martin L., Neitz, R. Jeffrey, Fang, Larry, Brogley, Louis, Wu, Jing, Konradi, Andrei W., Sham, Hing L., Tóth, Gergely, Pan, Hu, Yao, Nanhua, Artis, Dean R., Quinn, Kevin, Sauer, John-Michael, Powell, Kyle, Ren, Zhao, Bard, Frédérique, Yednock, Ted A., Griswold-Prenner, Irene
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated JNK3 IC 50 = 77 nM and retained the excellent broad kinase selectivity observed for the series. From high throughput screening, we discovered compound 1, the prototype for a series of disubstituted thiophene inhibitors of JNK which is selective towards closely related MAP kinases p38 and Erk2. Herein we describe the evolution of these compounds to a novel class of thiophene and thiazole JNK inhibitors that retain favorable solubility, permeability, and P-gp properties for development as CNS agents for treatment of neurodegeneration. Compound 61 demonstrated JNK3 IC 50 = 77 nM and retained the excellent broad kinase selectivity observed for the series.
ISSN:0960-894X
1464-3405
DOI:10.1016/j.bmcl.2010.10.066